BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34815798)

  • 1. Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing.
    Sun H; Zeng J; Miao Z; Lei KC; Huang C; Hu L; Su SM; Chan UI; Miao K; Zhang X; Zhang A; Guo S; Chen S; Meng Y; Deng M; Hao W; Lei H; Lin Y; Yang Z; Tang D; Wong KH; Zhang XD; Xu X; Deng CX
    Theranostics; 2021; 11(20):9967-9987. PubMed ID: 34815798
    [No Abstract]   [Full Text] [Related]  

  • 2. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
    Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
    Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.
    Bai F; Chan HL; Scott A; Smith MD; Fan C; Herschkowitz JI; Perou CM; Livingstone AS; Robbins DJ; Capobianco AJ; Pei XH
    Cancer Res; 2014 Nov; 74(21):6161-72. PubMed ID: 25239453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway.
    Bai F; Wang C; Liu X; Hollern D; Liu S; Fan C; Liu C; Ren S; Herschkowitz JI; Zhu WG; Pei XH
    Cell Death Dis; 2022 Mar; 13(3):195. PubMed ID: 35236825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis.
    Scott A; Bai F; Chan HL; Liu S; Ma J; Slingerland JM; Robbins DJ; Capobianco AJ; Pei XH
    Oncotarget; 2016 Dec; 7(51):84496-84507. PubMed ID: 27811360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA3 functions downstream of BRCA1 to suppress EMT in breast cancer.
    Bai F; Zhang LH; Liu X; Wang C; Zheng C; Sun J; Li M; Zhu WG; Pei XH
    Theranostics; 2021; 11(17):8218-8233. PubMed ID: 34373738
    [No Abstract]   [Full Text] [Related]  

  • 7. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
    Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
    Annunziato S; de Ruiter JR; Henneman L; Brambillasca CS; Lutz C; Vaillant F; Ferrante F; Drenth AP; van der Burg E; Siteur B; van Gerwen B; de Bruijn R; van Miltenburg MH; Huijbers IJ; van de Ven M; Visvader JE; Lindeman GJ; Wessels LFA; Jonkers J
    Nat Commun; 2019 Jan; 10(1):397. PubMed ID: 30674894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.
    Wang X; Bai F; Liu X; Peng B; Xu X; Zhang H; Fu L; Zhu WG; Wang B; Pei XH
    BMC Biol; 2024 Apr; 22(1):85. PubMed ID: 38627785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.
    Warmoes M; Jaspers JE; Pham TV; Piersma SR; Oudgenoeg G; Massink MP; Waisfisz Q; Rottenberg S; Boven E; Jonkers J; Jimenez CR
    Mol Cell Proteomics; 2012 Jul; 11(7):M111.013334. PubMed ID: 22366898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 Is Overexpressed in
    Puppe J; Opdam M; Schouten PC; Jóźwiak K; Lips E; Severson T; van de Ven M; Brambillasca C; Bouwman P; van Tellingen O; Bernards R; Wesseling J; Eichler C; Thangarajah F; Malter W; Pandey GK; Ozretić L; Caldas C; van Lohuizen M; Hauptmann M; Rhiem K; Hahnen E; Reinhardt HC; Büttner R; Mallmann P; Schömig-Markiefka B; Schmutzler R; Linn S; Jonkers J
    Clin Cancer Res; 2019 Jul; 25(14):4351-4362. PubMed ID: 31036541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone receptor A stability is mediated by glycogen synthase kinase-3β in the Brca1-deficient mammary gland.
    Wang S; Li Y; Hsu PH; Lee SY; Kim Y; Lee EYP
    J Biol Chem; 2013 Sep; 288(36):26265-26274. PubMed ID: 23880761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
    Wright MH; Robles AI; Herschkowitz JI; Hollingshead MG; Anver MR; Perou CM; Varticovski L
    Mol Cancer; 2008 Apr; 7():29. PubMed ID: 18394172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer.
    Weaver Z; Montagna C; Xu X; Howard T; Gadina M; Brodie SG; Deng CX; Ried T
    Oncogene; 2002 Aug; 21(33):5097-107. PubMed ID: 12140760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the BRCA1/long non-coding RNA NEAT1 signaling axis contributes to breast tumorigenesis.
    Lo PK; Zhang Y; Wolfson B; Gernapudi R; Yao Y; Duru N; Zhou Q
    Oncotarget; 2016 Oct; 7(40):65067-65089. PubMed ID: 27556296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
    Zuo Y; Ulu A; Chang JT; Frost JA
    Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin B1 stability is increased by interaction with BRCA1, and its overexpression suppresses the progression of BRCA1-associated mammary tumors.
    Choi EK; Lim JA; Kim JK; Jang MS; Kim SE; Baek HJ; Park EJ; Kim TH; Deng CX; Wang RH; Kim SS
    Exp Mol Med; 2018 Oct; 50(10):1-16. PubMed ID: 30327455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.
    Navaraj A; Finnberg N; Dicker DT; Yang W; Matthew EM; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2417-44. PubMed ID: 20038817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis.
    Ahmed KM; Tsai CY; Lee WH
    J Biol Chem; 2010 Feb; 285(7):4464-71. PubMed ID: 20007691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
    Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.